

MARKET REPORT



KOL Perspectives: Selective JAK inhibitors in IBD

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



KOL Perspectives: Selective JAK inhibitors in IBD

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

KOL Perspectives: Selective JAK inhibitors in IBD

KOL Perspectives: Selective JAK inhibitors in IBD

Summary

This KOL Insight briefing focuses on KOLs views of selective JAK inhibitors in IBD.

The briefing includes analysis of KOL opinion on the following topic areas -

- Maintenance data for selective JAKs in Crohn's disease
- Differentiating strategies for selective and non-selective JAKs in IBD
- Choice of primary endpoints for IBD trials □ Selective JAKs' expected efficacy in UC
- Real-world use of JAKs in IBD

Key Highlights

- KOLs were broadly impressed with upadacitinib's Week 52 data in Crohn's disease, but views of filgotinib's Week 20 data were mixed
- Most KOLs stated that upadacitinib maintenance data matched and reinforced positive expectations for upadacitinib in Crohn's disease
- KOL consensus is that mid-range doses (6/12mg), or extended release equivalents should be used in upadacitinib's Phase III program.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based
- Interviews performed during June 2017
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "selective JAK inhibitors in IBD"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Additional Details

Publisher : Global Data
Reference : GDHC051SP
Number of Pages : 26
Report Format : PDF
Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for KOL Perspectives: Selective JAK inhibitors in IBD [Report Updated: 05-01-2018]

- Table of ContentsExecutive SummaryBackgroundResearch Panel CompositionResults & ImplicationsAppendix

How to Buy...

KOL Perspectives: Selective JAK inhibitors in IBD [Report Updated: 05-01-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/224132>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.